Ignyta, Inc.
https://ignyta.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ignyta, Inc.
Stock Watch: Oncology Heritage Impedes Roche's Growth
Once a cancer drug powerhouse, Roche’s newer oncology launches were not taking up the slack caused by biosimilar competition to its former blockbusters. Something else was required.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.
BMS Hopes Turning Point Buyout Will Fare Better Than Roche’s Ignyta Acquisition
Bristol Myers Squibb thinks Turning Point’s ROS1/TRK inhibitor shows a best-in-class profile and potential to compete more successfully against Pfizer’s Xalkori than Roche’s Rozlytrek has.
Finance Watch: The Bigger The Better? Erasca, Imago Rise After IPOs
Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings.
Company Information
- Industry
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Actagene Oncology, Inc.
- NexDx, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice